{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089110","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.020218+00:00","generated_at":"2026-06-11T21:48:24.392984+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunome Q2 net loss $5.6M; merger with Morphimmune and $125M PIPE deal announced","bullets":["Q2 net loss $5.6M ($0.46 per share) on $4.3M AbbVie collaboration revenue; R&D $5.7M, G&A $4.2M.","Cash and cash equivalents $38.4M as of June 30, 2023.","Definitive merger agreement with Morphimmune to combine platforms, expected close by end of 2023.","Clay Siegall, ex-Seagen CEO, to serve as Chairman and CEO of combined company.","Concurrent $125M private placement from institutional investors to support 3 IND filings within 18 months post-close."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089110","json":"https://secwatch.observer/filing/0001104659-23-089110.json","markdown":"https://secwatch.observer/filing/0001104659-23-089110.md","text":"https://secwatch.observer/filing/0001104659-23-089110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/0001104659-23-089110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/tm2323035d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:48:24.392984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e39a4d2338a37f7bcb9327c8981977fdfb3010d3","claim":"Immunome Inc. reported the second quarter ended June 30, 2023 results: net income $5.6 million, or $0.46 per share, EPS $0.46 per share.","evidence_excerpt":"Net loss for the three months ended June 30, 2023 was $5.6 million, or $0.46 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/0001104659-23-089110-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$5.6 million, or $0.46 per share"},{"label":"EPS","value":"$0.46 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}